- Multiple sclerosis (MS) is a chronic autoimmune disorder that affects the central nervous system, leading to disability. The demand for MS treatments is significantly driven by the increasing prevalence of the disease and advancements in therapeutic options. For example, the number of MS cases in countries like the U.S., Canada, and European nations such as Sweden and Norway have been rising steadily due to greater awareness, improved diagnostic techniques, and better healthcare systems
- The demand for MS therapies is primarily driven by the need for disease-modifying therapies (DMTs), which aim to reduce the frequency and severity of relapses, slow disease progression, and manage symptoms
- For instance, advancements in DMTs is the approval of oral medications like Gilenya (fingolimod) and Tecfidera (dimethyl fumarate), which offer convenient alternatives to injectable treatments and have shown promising results in reducing MS relapses.
- Globally, disease-modifying therapies (DMTs) remain the cornerstone of the MS treatment market, followed by therapies aimed at symptom management. The development of oral medications and biologic therapies, such as monoclonal antibodies, has further improved treatment options for patients
